Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Two patients with the same type of cancer may have very different reactions to identical chemotherapy treatments because their cancers have different genetic causes. Doctors currently can’t predict which patients will have a good long-term response to a drug and which patients’ cancer will come back.

Researchers at the University of Virginia have developed a computer model that addresses this problem by using genetic analysis of tumors to predict which chemotherapy regimen will do patients the most good. The model has initially been tested in bladder and breast cancer, but it seems to have predictive power in all cancer types. The researchers are integrating the model into clinical trials to test whether it can be used to select the patients most likely to respond to a particular drug. They hope it will eventually be used routinely to help doctors quickly find the best treatment for cancer patients.

In a test of the model in two large trials of drugs for breast cancer, the model predicted with 85 percent accuracy which patients would and would not respond to treatment.

Dan Theodorescu, director of the Paul Mellon Prostate Cancer Institute, at the University of Virginia, believes that his group’s model is the first of its kind. It was developed using a database of information on about 60 human-cancer-cell lines maintained by the National Cancer Institute. This database includes information about how these cancer cells respond to more than 100,000 compounds, including all anticancer therapies approved by the Food and Drug Administration. The model also draws on gene-expression analysis of these 60 cancer types–that is, what genes they have and how they are using them.

Theodorescu says that his model uses gene-expression analysis as a kind of Rosetta stone for translating drug sensitivity in the 60 initial cell lines into a prediction of drug sensitivity in whatever tumor researchers are studying. He suggests that the model will also have predictive power for the many other cancer types not included in the initial group, including lung and pancreatic cancer and lymphomas.

Theodorescu and his collaborators also showed that the model could predict how patients would respond to cancer drugs. He is planning studies and clinical trials with researchers and centers around the country to validate the model across all major human cancers.

“This is a very innovative approach,” says W. Marston Linehan, chief of urologic oncology at the National Cancer Institute’s Center for Cancer Research.

“Scientists have been trying to apply [genetic analysis] to cancer treatment, but it hasn’t panned out the way we’d like,” says Cheryl Lee, associate professor of urology at the University of Michigan Comprehensive Cancer Center. “What [Theodorescu] is doing with [his model] is very novel because it uses computer modeling not only to discern tissue types, but [he] literally tries to match patients with chemotherapeutics.” Lee is part of a Michigan group that is collaborating with Theodorescu on a bladder-cancer clinical trial incorporating the model.

2 comments. Share your thoughts »

Credit: Proceedings of the National Academy of Sciences.

Tagged: Biomedicine, cancer, drugs, tumor, chemotherapy

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me